« Back
Home /
Bortezomib

Bortezomib

Item no.	HY-10227-50mg
Manufacturer	MedChem Express
CASRN	179324-69-7
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 500 mg 50 mg 5 mg
Category	Oncology Metabolism Cholesterol & Lipid Metabolism Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	99.97
Citations	[1]Adams J, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999 Jun 1;59(11):2615-22.\|[2]Shahshahan MA, et al. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastaticmelanoma: basic and clinical aspects. Am J Cancer Res. 2011;1(7):913-24.\|[3]Pérez-Galán P, et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006 Jan 1;107(1):257-64.\|[4]Yerlikaya A, et al. Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10 melanoma cell line. Mol Med Rep. 2010 Mar-Apr;3(2):333-9.\|[5]Mujtaba T, et al. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med. 2011 Dec;12(67):471-80.\|[6]Fernández Y, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem. 2006 Jan 13;281(2):1107-18.
Smiles	OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PS-341,LDP-341,NSC 681239
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; NF-κB; Proteasome
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	384.24
Product Description	Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 50 mg/mL (ultrasonic)\|Ethanol: 66.67 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis; Autophagy; Metabolic Enzyme/Protease; NF-κB
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10227-50mg-safety-datasheet.pdf